Description

Product Description

Background

Anticoagulant therapies such as unfractionated heparin (UFH) and low molecular weight heparins (LMWHs) are widely used for preventing and treating thromboembolic disorders. However, the lack of safe and effective reversal agents has been a significant limitation in clinical and research contexts. Delparantag (PMX-60056), a synthetic salicylamide derivative, has emerged as a promising reversal compound due to its strong affinity for heparin molecules and its ability to neutralize anticoagulation activity.

Chemical Nature

• Class: Salicylamide derivative

• Molecular Identity: Synthetic small molecule

• Mechanism: Electrostatic interaction with negatively charged heparin chains, leading to neutralization of anticoagulant effects

Importance in Research

Delparantag provides researchers with a tool to explore:

• The mechanisms of anticoagulant neutralization

• The pharmacology of heparin reversal

• Safer approaches to managing bleeding complications in experimental settings

• Comparative studies with traditional reversal agents like protamine sulfate

Advantages Over Other Agents

• Unlike protamine sulfate, Delparantag exhibits fewer hemodynamic effects in experimental studies.

• Its small-molecule nature may allow for more predictable pharmacokinetics.

• Applicable for both UFH and LMWH neutralization.

Product Specifications

Mechanism of Action & Research Applications

Mechanism of Action

Heparins exert their anticoagulant effect by enhancing the activity of antithrombin III, thereby inhibiting thrombin and factor Xa. Delparantag directly binds to negatively charged sulfate groups on heparin molecules, neutralizing their activity. This process prevents heparin from potentiating antithrombin activity, thus restoring normal coagulation function in research models.

Research Applications

• Anticoagulation Reversal

  • Enables rapid neutralization of UFH and LMWH effects in bleeding studies.

• Surgical Models

  • Facilitates controlled bleeding and reversal studies in preclinical cardiovascular and surgical experiments.

• Comparative Studies

  • Provides a model for comparing novel reversal agents versus protamine sulfate.

• Pharmacological Research

  • Offers insights into small-molecule design for anticoagulation reversal.

• Safety and Toxicity Studies

  • Allows evaluation of off-target effects and immune responses relative to protein-based reversal agents.

    

Side Effects (For Reference in Research Models)

Experimental studies have noted the following considerations when using Delparantag in laboratory settings:

• Dose-Dependent Responses: Higher doses may cause overcorrection of coagulation.

• Potential Rebound Anticoagulation: Some models suggest transient reactivation of heparin.

• Hemodynamic Effects: While milder than protamine, slight blood pressure changes may occur.

• Immune System Considerations: Being a small molecule, Delparantag appears to induce fewer hypersensitivity reactions than protein-based agents.

• Solvent Considerations: Improper dissolution can affect reproducibility.

Researchers are encouraged to carefully titrate doses, monitor coagulation parameters, and validate results across models.

Disclaimer

Delparantag is a For laboratory research use only. Not for human or veterinary use.Please strictly abide by local laws and regulations

Keywords

• Delparantag CAS 872454-31-4

• PMX-60056 heparin reversal

• Delparantag UFH LMWH neutralization

• Salicylamide derivative anticoagulant reversal

• GMP supplier Delparantag

• Delparantag bleeding model research

• Small molecule heparin reversal agent

• Experimental anticoagulation pharmacology

• Delparantag protamine alternative

• UFH LMWH reversal peptide